# MATERIAL SAFETY DATA SHEET

## 1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY

<table>
<thead>
<tr>
<th>Material</th>
<th>Telmisartan and Hydrochlorothiazide Tablets USP 40 mg/12.5 mg; 80 mg/12.5 mg and 80 mg/25 mg.</th>
</tr>
</thead>
</table>
| Manufacturer | Lupin Limited  
Goa 403 722  
INDIA. | |
| Distributor | Lupin Pharmaceuticals, Inc.  
Harborplace Tower, 21st Floor  
111, South Calvert Street  
Baltimore, MD 21202  
United States  
Tel.  001-410-576-2000  
Fax.  001-410-576-2221 | |

## 2. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>CAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Telmisartan USP</td>
<td>144701-48-4</td>
</tr>
<tr>
<td>Hydrochlorothiazide USP</td>
<td>00058-93-5</td>
</tr>
</tbody>
</table>

## 3. HAZARDOUS IDENTIFICATION

### Fire and Explosion

Assume that this product is capable of sustaining combustion.

### Health

Telmisartan and hydrochlorothiazide tablets are contraindicated in patients with known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan, hydrochlorothiazide, or any other component of this product.

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.

Do not co-administer aliskiren with telmisartan and hydrochlorothiazide in patients with diabetes.

### Environment

No information is available about the potential of this product to produce adverse environmental effects.
4. FIRST AID MEASURES

Ingestion
If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

Inhalation
Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

Skin Contact
Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

Eye Contact
Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

OVERDOSAGE

Telmisartan
Limited data are available with regard to overdosage in humans. The most likely manifestations of overdosage with telmisartan would be hypotension, dizziness and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted. Telmisartan is not removed by hemodialysis.

Hydrochlorothiazide
The most common signs and symptoms observed in patients are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias.
The degree to which hydrochlorothiazide is removed by hemodialysis has not been established.
The oral LD_{50} of hydrochlorothiazide is greater than 10 g/kg in both mice and rats.

5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards
Assume that this product is capable of sustaining combustion.

Extinguishing Media
Water spray, carbon dioxide, dry chemical powder or appropriate foam.

Special Firefighting Procedures
For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters.
6. ACCIDENTAL RELEASE MEASURES

Hazardous Combustion Products
Hazardous combustion or decomposition products are expected when the product is exposed to fire.

Personal Precautions
Wear protective clothing and equipment consistent with the degree of hazard.

Environmental Precautions
For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

Clean-up Methods
Collect and place it in a suitable, properly labeled container for recovery or disposal.

7. HANDLING AND STORAGE

Handling
No special precautions are necessary when handling packed product. In case of accident, avoid breathing dust from crushed tablets. Avoid contact with skin and eyes. Wash hands after use.

Storage
Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature].

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

9. PHYSICAL & CHEMICAL PROPERTIES

Physical Form
Telmisartan and Hydrochlorothiazide Tablets USP are available in three strengths:

40 mg/12.5 mg : supplied as oval shaped, biconvex, bilayer, uncoated tablets; where hydrochlorothiazide layer is red coloured and telmisartan layer is white to off-white in colour but may have red specks; debossed with 'M31' on one side and 'LU' on other side.

Bottle of 90's: NDC 68180-193-09
Unit Dose Blisters of 3 X 10s NDC 68180-193-13

80 mg/12.5 mg : supplied as capsule shaped, biconvex, bilayer, uncoated tablets; where hydrochlorothiazide layer is red coloured and telmisartan layer is white to off-white in colour but may have red specks; debossed with 'M32' on one side and 'LU' on other side.
Bottle of 90's: NDC 68180-194-09
Unit Dose Blisters of 3 X 10s NDC 68180-194-13

80 mg/25 mg : supplied as capsule shaped, biconvex, bilayer, uncoated tablets; where hydrochlorothiazide layer is yellow coloured and telmisartan layer is white to off-white in colour but may have yellow specks; debossed with 'M33' on one side and 'LU' on other side.

Bottle of 90's: NDC 68180-195-09
Unit Dose Blisters of 3 X 10s NDC 68180-195-13

### 10. STABILITY AND REACTIVITY

Stable under recommended storage conditions.

### 11. TOXICOLOGICAL INFORMATION

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

**Telmisartan and Hydrochlorothiazide**

No carcinogenicity, mutagenicity, or fertility studies have been conducted with the combination of telmisartan and hydrochlorothiazide.

**Telmisartan**

There was no evidence of carcinogenicity when telmisartan was administered in the diet to mice and rats for up to 2 years. The highest doses administered to mice (1000 mg/kg/day) and rats (100 mg/kg/day) are, on a mg/m² basis, about 59 and 13 times, respectively, the maximum recommended human dose (MRHD) of telmisartan. These same doses have been shown to provide average systemic exposures to telmisartan >100 times and >25 times, respectively, the systemic exposure in humans receiving the MRHD (80 mg/day).

Genotoxicity assays did not reveal any telmisartan-related effects at either the gene or chromosome level. These assays included bacterial mutagenicity tests with *Salmonella* and *E. coli* (Ames), a gene mutation test with Chinese hamster V79 cells, a cytogenetic test with human lymphocytes, and a mouse micronucleus test.

No drug-related effects on the reproductive performance of male and female rats were noted at 100 mg/kg/day (the highest dose administered), about 13 times, on a mg/m² basis, the MRHD of telmisartan. This dose in the rat resulted in an average systemic exposure (telmisartan AUC as determined on day 6 of pregnancy) at least 50 times the average systemic exposure in humans at the MRHD (80 mg/day).
Hydrochlorothiazide
Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600 mg/kg/day) or in male and female rats (at doses of up to approximately 100 mg/kg/day). The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice.

Hydrochlorothiazide was not genotoxic in vitro in the Ames mutagenicity assay of Salmonella typhimurium strains TA 98, TA 100, TA 1535, TA 1537, and TA 1538 and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations, or in vivo in assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the Drosophila sex-linked recessive lethal trait gene. Positive test results were obtained in the in vitro CHO Sister Chromatid Exchange (clastogenicity) assay, in the Mouse Lymphoma Cell (mutagenicity) assay, and in the Aspergillus nidulans non-disjunction assay.

Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg, respectively, prior to mating and throughout gestation.

12. ECOLOGICAL INFORMATION

No information available

13. DISPOSAL CONSIDERATION

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

14. TRANSPORT INFORMATION

<table>
<thead>
<tr>
<th>IATA/ICAO - Not Regulated</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IATA Proper shipping Name</td>
<td>N/A</td>
</tr>
<tr>
<td>IATA UN/ID No</td>
<td>N/A</td>
</tr>
<tr>
<td>IATA Hazard Class</td>
<td>N/A</td>
</tr>
<tr>
<td>IATA Packaging Group</td>
<td>N/A</td>
</tr>
<tr>
<td>IATA Label</td>
<td>N/A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IMDG - Not Regulated</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IMDG Proper shipping Name</td>
<td>N/A</td>
</tr>
<tr>
<td>IMDG UN/ID No</td>
<td>N/A</td>
</tr>
<tr>
<td>IMDG Hazard Class</td>
<td>N/A</td>
</tr>
<tr>
<td>IMDG Flash Point</td>
<td>N/A</td>
</tr>
<tr>
<td>IMDG Label</td>
<td>N/A</td>
</tr>
</tbody>
</table>
15. REGULATORY INFORMATION

No information available.

16. OTHER INFORMATION

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this MSDS.